We conducted a quantitative structure-activity relationship (QSAR) study based on a database 26 of 127 compounds previously tested against the liver stage of Plasmodium yoelii, in order to 27 develop a model capable of predicting the in vitro antimalarial activity of new compounds. 28
INTRODUCTION 55 56
Each year the malaria parasite Plasmodium falciparum infects 300-660 million persons 57 worldwide and causes several million deaths (26) . New antimalarial drugs are urgently 58 needed, especially considering the increasing prevalence of drug-resistant P. falciparum 59 strains and the lack of effective vaccines and vector control measures. Plasmodium liver stage 60 is an interesting drug target, as it precedes the emergence of blood stages that cause the 61 symptoms and complications of malaria. Drugs that inhibit parasite maturation within 62 hepatocytes could be used for short-term prophylaxis in endemic areas (refugees, travellers, 63 etc.). In addition, such drugs would be unlikely to select resistant strains, as the number of 64 mitoses that occur during hepatic schizogony is many orders of magnitude smaller than 65 during the erythrocyte stage, thereby limiting the risk of mutant selection. 66 67 Atovaquone and primaquine, licensed drugs, are currently the only drugs known to be 68 effective against liver stages. However, atovaquone does not act against dormant forms of P. 69 vivax and P. ovale and tends to select resistant clones amongst blood stages of P. falciparum, 70 while primaquine carries a high risk of acute hemolysis in glucose-6-phosphate 71 dehydrogenase-deficient patients, limiting the prophylactic use of these drugs. The later 72 limitation also applies to other related synthetic 8-aminoquinolines such as bulaquine (2) and 73 tafenoquine (28) . 74
75
The identification and assessment of candidate antimalarial drugs effective against exo-76 erythrocytic (EE) stages of Plasmodium is hampered by the lack of simple in vitro and in vivo 77 tests. Several mathematical approaches have been proposed to facilitate the search for new 78 active compounds. Equation systems linking structure and activity (QSAR studies) are 79 particularly relevant, and can be applied to large libraries of compounds for virtual 80 computational screening (5, 15) . However, these models require good structural descriptors 81 that reliably represent the molecular features responsible for the relevant biological activity. 82
Molecular topology is one way of describing molecular structures. It follows a two-83 dimensional approach, taking into account the internal atomic arrangement. The structure of 84 each molecule is represented by specific subsets of topological indices (TI) (4) . These indices, 85 when well chosen, provide a unique way of characterizing a molecular structure (14) . 86
Moreover, they correlate with many physical, chemical and biological properties of 87 structurally heterogeneous groups of compounds and can be used to find out new drugs (7) . 88
These models have already been used to predict the activity of candidate antimicrobial and 89 antimalarial agents (9-12, 18, 19, 21) . 90
91
The aim of this study was to develop and assess QSAR models based on molecular topology, 92 in order to identify new compounds active on the liver stages of Plasmodium, as well as 93 predicting physicochemical parameters influencing intestinal absorption. 94 PRn (number of pairs of ramifications at topological distance n, with n ranging from 0 to 4), 109
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Vn (number of vertices with topological valence n, with n=3 or 4), and other graph-theoretical 110 descriptors (not outlined here, as they were not selected for the final model). All descriptors 111 were calculated with Desmol11 software (23) . 112
113

Linear Discriminant Analysis (LDA) 114
LDA is a pattern-recognition method providing a classification model based on the 115 combination of variables that best predicts the category or group to which a given compound 116 belongs. Database compounds were allocated to highly active, active, and inactive groups 117
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on November 3, 2017 by guest http://aac.asm.org/ Downloaded from according to their IC 50, using a first cutoff of 25 µM to separate active compounds (IC 50 < 25 118 µM) from inactive compounds (IC 50 > 25 µM), and a second cut off of 1µM to separate 119 highly active (IC 50 < 1 µM) from weakly to moderately active compounds (1 µM < IC 50 < 10 120 µM). The cutoff was applicable as it clearly distinguished among inactive, active and highly 121 active drugs. LDA was then applied to these three groups in order to obtain two discriminant 122 functions, DF1 and DF2, which classified a compound as active/inactive or active/highly 123 active, respectively. The independent variables in this study were the calculated TI, and the 124 discriminatory property was the activity against the liver stage of Plasmodium. With these diagrams, we can visually determine the intervals in which there is a maximum 149 probability of finding new active compounds and a minimum probability of finding inactive 150 compounds. 151
152
Topological virtual screening 153
The topological model selected and constructed with the DF1 and DF2 functions was used to 154 find new antimalarial agents from among a database of 479 compounds listed in the Merck 155 index. This database was composed of drugs belonging to several therapeutic categories 156 (antineoplastics, antivirals, antifungals, antibacterials, etc.). A first selection step was 157 performed by using the discriminant function DF1. The DF2 function was then used to sort 158 the compounds selected as active by DF1. PDDs were used to assign thresholds to 159 discriminate active from inactive compounds with the highest probability of success. The 160 compounds predicted to be active by the two equations (DF1 and DF2) within the pre-161 established cutoffs were considered potentially active. Among these, several commercially 162 available compounds were assayed in vitro against the liver stage of P. y. yoelii. RSS is the residual sum of squares for the best test subsets, p' is the number of independent 178 variables in the subsets (including the constant), n is the number of cases, and s 2 is the 179 residual mean square based on the regression using all independent variables. The stability of 180 the selected mathematical model can be evaluated through a cross-validation by leave-one-181 out: to do this, one compound of the set is extracted, and the model is recalculated using as 182 training set the remaining N -1 compounds. The property is then predicted for the removed 183 element. This process is repeated for all the compounds of the set, obtaining a prediction for 184 every one. 185
186
In vitro antimalarial activity against liver stage of Plasmodium 187
The in vitro activity of drugs was studied against hepatic stages of P. y. yoelii and only drugs 188 with complete parasite inhibition were examined for activity against P. falciparum. 189
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Pharmacological tests were performed as previously described (17 revealed with polyclonal HSPi72 serum followed by goat anti-mouse Ig conjugated to 200 fluorescein isothiocyanate (FITC). Schizonts were counted to determine the 50% inhibitory 201 concentration (IC 50 ) by linear regression, as previously described (17) . 202
203
Toxicity assay 204
Toxicity was determined by using the colorimetric MTT assay (22) . Briefly, mouse 205 hepatocyte cultures were prepared in 96-well plates as described above. Drugs were tested in 206 triplicate wells at eight concentrations ranging from 6.4x10 -3 µM to 100 µM. One hundred 207 microliters of 0.5 mg/ml MTT (5 mg/ml MTT in water, diluted 10x in William's medium 208 without foetal bovin serum) was added to each well, and the plates were incubated for 4 hours 209 (37°C, 5% CO 2 ). The medium was discarded, and the cells were resuspended in ethanol and 210 DMSO (50/50, v/v). The plates were read in an ELISA plate reader (550 nm absorbance 211 wavelength, 620 nm reference wavelength). The results were expressed as the percentage 212 change in viability compared to drug-free control cultures. Viability data were used to plot 213 
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RESULTS
217
Mathematical modelling 219
The test compounds were classified according to their structure and their activity against 220
Plasmodium, based on a mathematical model consisting of two equations. 
Prediction of the octanol/water partition constant (logP) by MLR analysis 278
Given that log (P) is representative of the hydrophobicity and oral absorption of a molecule, 279
we developed a topological equation capable of predicting log (P). The equation was built up 280 from a set of 57 structurally heterogeneous compounds for which experimental log (P) values 281 were available. Results were validated using the leave-one-out cross-validation. 282
The best predictive equation was: log (P) = 13.67 +9. The in vitro validation of the model was performed using cultures of P. y. yoelii, but we can 395 reasonably assume that such results can be extrapolated to P. falciparum (most of the 396 molecules known so far to prevent hepatic development are efficient in both rodent and 397
human Plasmodium) (17, 27 ). Furthermore we have tested two ionophores in vitro (monensin 398 and nigericin) against P. falciparum liver stage and complete inhibition of parasite 399 development was observed. However, there are exceptional examples for discrepancy 400 between human and rodent species: while inhibiting in vitro and in vivo development of P. 401 yoelii (20) , for instance doxycycline has never been shown to have any effect on hepatic 402 multiplication of P. falciparum in man in endemic areas (24 Comparison between experimental (y axis) and calculated (x axis) log P values for 57 compounds. 
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